PMID- 33460480
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1365-2265 (Electronic)
IS  - 0300-0664 (Linking)
VI  - 94
IP  - 5
DP  - 2021 May
TI  - Which parameters predict the beneficial effect of GnRHa treatment on height in 
      girls with central precocious puberty?
PG  - 804-810
LID - 10.1111/cen.14420 [doi]
AB  - OBJECTIVE: Data about GnRHa on adult height in girls with central precocious 
      puberty (CPP) have shown variable results, ranging from improvement of growth 
      prognosis to lack of any benefit. This study was designed to delineate the 
      criteria to decide which girls with idiopathic CPP (iCPP) will have a height 
      benefit from GnRHa treatment. DESIGN: Retrospective PATIENTS: 102 girls with iCPP 
      who had reached final height (FH) were included. MEASUREMENTS: Auxological, 
      hormonal and radiological findings at treatment onset, and FHs were extracted 
      from records. RESULTS: Most important factor affecting height gain was 
      chronological age (CA) at treatment onset. All the girls treated </=6.4 years of 
      age achieved a height gain of >/=1SDS, while none of the girls treated >/=8.3 years 
      of age made the target. 75.6% of patients who started GnRHa between the ages of 
      6.4 and 8.3 years had a height gain of >/=1SDS. Most important factors affecting 
      height gain in those treated 6.4-8.3 years were advanced bone age (BA), basal 
      estradiol (E(2) ) and pubertal stage (r(2) : 0.906; P < .001). All individuals 
      with BA advancement of >/=2.6 years or E(2) of >/=32.6 pg/ml or pubertal stage of >/=3 
      had significant height gain, and none of the cases with BA advancement of 
      <2 years or E(2) of <21.5 pg/ml or pubertal stage of <2 had a height gain of 
      >/=1SDS. CONCLUSIONS: Treatment with GnRHa is unquestionably beneficial to improve 
      FH in girls with iCPP when initiated </=6.4 years of age. GnRHa treatment after 
      8.3 years of age may not improve FH. Girls between the ages of 6.4 and 8.3 years 
      at presentation can have a better height gain if BA (>/=2.6 years over CA) and 
      pubertal findings (pubertal stage >/=3 or E(2) >/=32.6 pg/ml) are well-advanced.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Vuralli, Dogus
AU  - Vuralli D
AUID- ORCID: 0000-0002-4011-2299
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of 
      Medicine, Hacettepe University, Ankara, Turkey.
FAU - Gonc, Nazli E
AU  - Gonc NE
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of 
      Medicine, Hacettepe University, Ankara, Turkey.
FAU - Ozon, Zeynep Alev
AU  - Ozon ZA
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of 
      Medicine, Hacettepe University, Ankara, Turkey.
FAU - Kandemir, Nurgun
AU  - Kandemir N
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of 
      Medicine, Hacettepe University, Ankara, Turkey.
FAU - Alikasifoglu, Ayfer
AU  - Alikasifoglu A
AD  - Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of 
      Medicine, Hacettepe University, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210207
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
MH  - Body Height
MH  - Child
MH  - Female
MH  - Gonadotropin-Releasing Hormone
MH  - Growth Disorders
MH  - Humans
MH  - *Puberty, Precocious/drug therapy
MH  - Retrospective Studies
OTO - NOTNLM
OT  - body height
OT  - bone age measurement
OT  - central precocious puberty
OT  - child
OT  - gonadotropin-releasing hormone
OT  - idiopathic sexual precocity
OT  - leuprolide
EDAT- 2021/01/19 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/01/18 17:06
PHST- 2021/01/01 00:00 [revised]
PHST- 2020/09/16 00:00 [received]
PHST- 2021/01/05 00:00 [accepted]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/01/18 17:06 [entrez]
AID - 10.1111/cen.14420 [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2021 May;94(5):804-810. doi: 10.1111/cen.14420. Epub 2021 
      Feb 7.